BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27325687)

  • 1. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
    Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
    Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Drug Imaging:
    Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
    J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model.
    Caretti V; Zondervan I; Meijer DH; Idema S; Vos W; Hamans B; Bugiani M; Hulleman E; Wesseling P; Vandertop WP; Noske DP; Kaspers G; Molthoff CF; Wurdinger T
    Brain Pathol; 2011 Jul; 21(4):441-51. PubMed ID: 21159008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma.
    Veldhuijzen van Zanten SEM; Sewing ACP; van Lingen A; Hoekstra OS; Wesseling P; Meel MH; van Vuurden DG; Kaspers GJL; Hulleman E; Bugiani M
    J Nucl Med; 2018 Apr; 59(4):612-615. PubMed ID: 28818988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
    van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
    Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
    Kossatz S; Carney B; Schweitzer M; Carlucci G; Miloushev VZ; Maachani UB; Rajappa P; Keshari KR; Pisapia D; Weber WA; Souweidane MM; Reiner T
    Cancer Res; 2017 Apr; 77(8):2112-2123. PubMed ID: 28108511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 89Zr-bevacizumab PET imaging in primary breast cancer.
    Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
    J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
    Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of
    Tinkle CL; Duncan EC; Doubrovin M; Han Y; Li Y; Kim H; Broniscer A; Snyder SE; Merchant TE; Shulkin BL
    J Nucl Med; 2019 Mar; 60(3):312-319. PubMed ID: 30072503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
    Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
    Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
    Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
    J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and pharmacokinetics of [
    García-Varela L; Codesido J; Perez-Pedrosa A; Muñoz-González M; Ramos-Docampo E; Rey-Bretal D; García-Otero X; Gómez-Lado N; Turrero A; Beiroa D; Rodríguez-Perez AI; Vidal A; Fernández-Ferreiro A; Pubul V; Aguiar P
    Int J Pharm; 2024 Mar; 652():123795. PubMed ID: 38224761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography.
    Golestani R; Zeebregts CJ; Terwisscha van Scheltinga AG; Lub-de Hooge MN; van Dam GM; Glaudemans AW; Dierckx RA; Tio RA; Suurmeijer AJ; Boersma HH; Nagengast WB; Slart RH
    Mol Imaging; 2013 Jun; 12(4):235-43. PubMed ID: 23651501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.